US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

147.06

+1.310.90%

Volume:132.42K

Turnover:19.61M

Market Cap:2.12B

PE:-30.03

High:151.54

Open:148.59

Low:145.14

Close:145.75

52wk High:161.38

52wk Low:49.81

Shares:14.41M

Float Shares:8.40M

Volume Ratio:0.75

T/O Rate:1.58%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.8978

EPS(LYR):-3.7076

ROE:-46.63%

ROA:-22.05%

PB:9.77

PE(LYR):-39.66

Loading ...

Overview Company News Filings

Palvella Therapeutics, Inc Q1 EPS USD -1.2

THOMSON REUTERS

Earnings Flash (PVLA) Palvella Therapeutics Posts Q1 Net Loss $1.20 a Share, vs. FactSet Est of $0.97 Net Loss a Share

MT Newswires Live

Palvella Q1 net loss widens to $15.8 million; R&D expenses rise to $9.3 million

Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate

Benzinga Earnings

Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

BRIEF-Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas

Palvella doses first patients in Phase 2 LOTU trial of QTORIN rapamycin gel

Palvella Therapeutics Inc - Topline Results From Phase 2 Lotu Trial Expected in Second Half of 2027

THOMSON REUTERS

Palvella Therapeutics to host first-quarter financial results conference call

Is It Too Late To Consider Palvella Therapeutics (PVLA) After Its 386.8% One Year Surge?

Simply Wall St.

Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA)

Palvella reports Phase 3 SELVA, Phase 2 TOIVA QTORIN rapamycin results slated for ISSVA 2026

Palvella COO Kathleen Goin disposes of 4,302 shares worth $549,900

Palvella Therapeutics director John Doux files initial beneficial ownership statement

Press Release: Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors

Press Release: Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

Palvella director George M. Jenkins acquires PVLA shares worth 0.1 million

Stock Track | Palvella Therapeutics Soars 5.58% Intraday on Analyst Price Target Hikes

Palvella Therapeutics Inc : Raymond James Raises Target Price to $225 From $193

THOMSON REUTERS

Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/PVLA/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PVLA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","market":"US","secType":"STK","nameCN":"Palvella Therapeutics","latestPrice":147.06,"timestamp":1787684227686,"preClose":145.75,"halted":0,"volume":132418,"delay":0,"changeRate":0.008987993138936551,"floatShares":8398100,"shares":14408407,"eps":-4.897784,"marketStatus":"Trading","change":1.31,"latestTime":"08-25 14:57:17 EDT","open":148.59,"high":151.54,"low":145.14,"amount":19612696.14018,"amplitude":0.043911,"askPrice":147.48,"askSize":20,"bidPrice":146.7,"bidSize":58,"shortable":3,"etf":0,"ttmEps":-4.897784,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"listingDate":1435636800000,"exchange":"NASDAQ","adjPreClose":145.75,"preHourTrading":{"tag":"盘前","latestPrice":148.48,"preClose":145.75,"latestTime":"09:29 EDT","volume":5691,"amount":838503.23277,"timestamp":1787664599999,"change":2.73,"changeRate":0.018731,"amplitude":0.089057},"postHourTrading":{"tag":"盘后","latestPrice":145.75,"preClose":145.75,"latestTime":"19:30 EDT","volume":3417,"amount":498022.65,"timestamp":1787614206555,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.748629,"impliedVol":0.5079,"impliedVolPercentile":0.0359},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PVLA\",,,,,undefined,":{"symbol":"PVLA","floatShares":8398100,"roa":"-22.05%","roe":"-46.63%","lyrEps":-3.707588,"volumeRatio":0.748629,"shares":14408407,"dividePrice":0,"high":151.54,"amplitude":0.043911,"preClose":145.75,"low":145.14,"week52Low":49.8057,"pbRate":"9.77","week52High":161.38,"institutionHeld":0,"latestPrice":147.06,"committee":0.487179,"eps":-4.897784,"divideRate":0,"volume":132418,"delay":0,"ttmEps":-4.897784,"open":148.59,"prevYearClose":104.67,"prevWeekClose":142.04,"prevMonthClose":139.04,"prevQuarterClose":152.82,"fiveDayClose":150.42,"twentyDayClose":142.84,"sixtyDayClose":118.46},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PVLA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-04","symbol":"PVLA","fiscalQuarterEnding":"2026/06","expectedEps":-1.16,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785816000000,"reportTimeType":"pre","actualEps":-1.52},{"market":"US","date":"2026-05-07","symbol":"PVLA","fiscalQuarterEnding":"2026/03","expectedEps":-0.9,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.2},{"market":"US","date":"2026-03-31","symbol":"PVLA","fiscalQuarterEnding":"2025/12","expectedEps":-0.95,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1774929600000,"reportTimeType":"pre","actualEps":-1.08},{"market":"US","date":"2025-11-11","symbol":"PVLA","fiscalQuarterEnding":"2025/09","expectedEps":-0.85,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762837200000,"reportTimeType":"pre","actualEps":-1.03},{"market":"US","date":"2025-08-14","symbol":"PVLA","fiscalQuarterEnding":"2025/06","expectedEps":-0.78,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"pre","actualEps":-0.86}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PVLA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PVLA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":16,"updateTime":1778731200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PVLA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PVLA","date":"2026-08-24","current":-30.183038,"percent":0.338095,"low":-60.48704,"twenty":-36.922579,"median":-27.974807,"eighty":-10.857858,"high":46.119317,"avg":-19.601633,"sd":24.449879,"marketCap":2046570130},"quantilePoints":[{"date":"2024-12-20","current":19.163371,"twenty":19.017062,"median":19.163371,"eighty":20.457893,"marketCap":135216749},{"date":"2024-12-27","current":19.083855,"twenty":18.842127,"median":19.083855,"eighty":19.659551,"marketCap":134655684},{"date":"2025-01-03","current":21.071757,"twenty":18.969352,"median":19.083855,"eighty":19.907642,"marketCap":148682317},{"date":"2025-01-10","current":22.216788,"twenty":19.083855,"median":19.083855,"eighty":21.987782,"marketCap":156761658},{"date":"2025-01-17","current":20.960435,"twenty":19.083855,"median":20.523096,"eighty":21.13537,"marketCap":147896826},{"date":"2025-01-24","current":19.863113,"twenty":19.083855,"median":20.650322,"eighty":21.071757,"marketCap":140154124},{"date":"2025-01-31","current":20.674177,"twenty":19.083855,"median":20.658273,"eighty":21.151273,"marketCap":145876991},{"date":"2025-02-07","current":24.729496,"twenty":19.083855,"median":20.674177,"eighty":22.089563,"marketCap":174491323},{"date":"2025-02-14","current":31.090781,"twenty":19.083855,"median":20.912725,"eighty":23.46519,"marketCap":219376551},{"date":"2025-02-21","current":30.565975,"twenty":19.147468,"median":20.992241,"eighty":24.783567,"marketCap":215673520},{"date":"2025-02-28","current":30.804523,"twenty":19.723165,"median":21.111515,"eighty":29.913943,"marketCap":217356716},{"date":"2025-03-07","current":39.042387,"twenty":20.066674,"median":21.469337,"eighty":30.728188,"marketCap":275483086},{"date":"2025-03-14","current":43.678174,"twenty":20.34657,"median":22.439433,"eighty":31.793703,"marketCap":308193196},{"date":"2025-03-21","current":44.751641,"twenty":20.49288,"median":23.46519,"eighty":33.810231,"marketCap":315767578},{"date":"2025-03-28","current":44.688028,"twenty":20.604203,"median":24.292158,"eighty":40.654974,"marketCap":315318726},{"date":"2025-04-04","current":-15.155991,"twenty":19.723165,"median":23.46519,"eighty":39.236406,"marketCap":264229553},{"date":"2025-04-11","current":-13.752893,"twenty":19.083855,"median":22.439433,"eighty":38.266311,"marketCap":239767934},{"date":"2025-04-17","current":-15.396161,"twenty":19.00752,"median":21.77945,"eighty":36.545583,"marketCap":268416676},{"date":"2025-04-25","current":-16.047148,"twenty":-12.608925,"median":21.151273,"eighty":34.239617,"marketCap":279765986},{"date":"2025-05-02","current":-15.493342,"twenty":-14.192783,"median":21.008144,"eighty":33.36176,"marketCap":270110923},{"date":"2025-05-09","current":-14.42287,"twenty":-14.682214,"median":20.912725,"eighty":33.091405,"marketCap":251448313},{"date":"2025-05-16","current":-10.548775,"twenty":-14.614161,"median":20.674177,"eighty":32.251716,"marketCap":243497378},{"date":"2025-05-23","current":-10.577479,"twenty":-14.552086,"median":20.64237,"eighty":31.796884,"marketCap":244159956},{"date":"2025-05-30","current":-11.868448,"twenty":-14.483678,"median":20.515145,"eighty":31.510626,"marketCap":273959378},{"date":"2025-06-06","current":-11.250599,"twenty":-14.245514,"median":19.990339,"eighty":31.090781,"marketCap":259697570},{"date":"2025-06-13","current":-12.65393,"twenty":-13.898957,"median":19.083855,"eighty":30.976278,"marketCap":292090669},{"date":"2025-06-20","current":-9.82332,"twenty":-13.773118,"median":19.083855,"eighty":30.785439,"marketCap":226751689},{"date":"2025-06-27","current":-9.876005,"twenty":-13.751337,"median":19.083855,"eighty":30.680478,"marketCap":227967812},{"date":"2025-07-03","current":-11.552339,"twenty":-13.745115,"median":18.829404,"eighty":30.565975,"marketCap":266662639},{"date":"2025-07-11","current":-12.902986,"twenty":-13.143371,"median":-9.82332,"eighty":30.216104,"marketCap":297839615},{"date":"2025-07-18","current":-14.957693,"twenty":-13.611836,"median":-10.196903,"eighty":29.977556,"marketCap":345268417},{"date":"2025-07-25","current":-18.501942,"twenty":-13.979479,"median":-10.548775,"eighty":29.89804,"marketCap":427080338},{"date":"2025-08-01","current":-17.520089,"twenty":-14.593892,"median":-10.570486,"eighty":26.844623,"marketCap":404416225},{"date":"2025-08-08","current":-18.703103,"twenty":-14.909501,"median":-10.577479,"eighty":25.683689,"marketCap":431723718},{"date":"2025-08-15","current":-17.957373,"twenty":-15.155991,"median":-10.795594,"eighty":24.999851,"marketCap":509666156},{"date":"2025-08-22","current":-19.99406,"twenty":-15.421442,"median":-10.987175,"eighty":24.729496,"marketCap":567471411},{"date":"2025-08-29","current":-19.990163,"twenty":-15.528887,"median":-11.165181,"eighty":23.854819,"marketCap":567360814},{"date":"2025-09-05","current":-21.096831,"twenty":-16.235493,"median":-11.305678,"eighty":23.549477,"marketCap":598770263},{"date":"2025-09-12","current":-22.776317,"twenty":-17.271569,"median":-11.413443,"eighty":23.46678,"marketCap":646437419},{"date":"2025-09-19","current":-23.006223,"twenty":-17.715742,"median":-11.554734,"eighty":23.433384,"marketCap":652962621},{"date":"2025-09-26","current":-22.480166,"twenty":-18.057474,"median":-11.868448,"eighty":22.814749,"marketCap":638032073},{"date":"2025-10-03","current":-24.405145,"twenty":-18.52589,"median":-11.961844,"eighty":22.305846,"marketCap":692666818},{"date":"2025-10-10","current":-27.312096,"twenty":-18.938434,"median":-12.127082,"eighty":22.115008,"marketCap":775171919},{"date":"2025-10-17","current":-28.500595,"twenty":-19.602341,"median":-12.457671,"eighty":21.593382,"marketCap":808903898},{"date":"2025-10-24","current":-27.783599,"twenty":-20.103168,"median":-12.65393,"eighty":21.227608,"marketCap":788554114},{"date":"2025-10-31","current":-30.558062,"twenty":-20.870432,"median":-12.719639,"eighty":21.154454,"marketCap":867298929},{"date":"2025-11-07","current":-30.639894,"twenty":-21.250362,"median":-12.96286,"eighty":21.08766,"marketCap":869621458},{"date":"2025-11-14","current":-28.915921,"twenty":-22.006325,"median":-13.231068,"eighty":21.033589,"marketCap":952837445},{"date":"2025-11-21","current":-32.881534,"twenty":-22.215189,"median":-13.745115,"eighty":20.998602,"marketCap":1083512294},{"date":"2025-11-28","current":-36.922579,"twenty":-22.816843,"median":-13.778174,"eighty":20.973157,"marketCap":1216672807},{"date":"2025-12-05","current":-33.693335,"twenty":-23.242364,"median":-14.278382,"eighty":20.931809,"marketCap":1110262762},{"date":"2025-12-12","current":-34.763763,"twenty":-24.512694,"median":-14.593892,"eighty":20.769596,"marketCap":1145535502},{"date":"2025-12-19","current":-34.569792,"twenty":-27.267674,"median":-14.831115,"eighty":20.674177,"marketCap":1139143797},{"date":"2025-12-26","current":-38.014559,"twenty":-27.693195,"median":-14.933597,"eighty":20.674177,"marketCap":1252655736},{"date":"2026-01-02","current":-37.597882,"twenty":-28.489684,"median":-15.118842,"eighty":20.670996,"marketCap":1238925408},{"date":"2026-01-09","current":-34.979285,"twenty":-28.647112,"median":-15.258978,"eighty":20.655092,"marketCap":1152637396},{"date":"2026-01-16","current":-37.350031,"twenty":-29.232399,"median":-15.408801,"eighty":20.639189,"marketCap":1230758230},{"date":"2026-01-23","current":-33.075504,"twenty":-29.325414,"median":-15.443563,"eighty":20.626467,"marketCap":1089903999},{"date":"2026-01-30","current":-29.418807,"twenty":-29.517639,"median":-15.528887,"eighty":20.515145,"marketCap":969408531},{"date":"2026-02-06","current":-27.453961,"twenty":-29.48062,"median":-16.091391,"eighty":20.403822,"marketCap":904662930},{"date":"2026-02-13","current":-29.461912,"twenty":-29.48062,"median":-17.007828,"eighty":20.117564,"marketCap":970828909},{"date":"2026-02-20","current":-29.573265,"twenty":-29.488024,"median":-17.242297,"eighty":19.914003,"marketCap":974498221},{"date":"2026-02-27","current":-60.48704,"twenty":-29.707799,"median":-17.512905,"eighty":19.303319,"marketCap":1993168926},{"date":"2026-03-06","current":-55.02714,"twenty":-30.090518,"median":-17.81704,"eighty":19.099758,"marketCap":1813254325},{"date":"2026-03-13","current":-55.699943,"twenty":-30.574428,"median":-17.963839,"eighty":19.083855,"marketCap":1835424534},{"date":"2026-03-20","current":-46.447881,"twenty":-31.137829,"median":-18.431476,"eighty":19.083855,"marketCap":1530550575},{"date":"2026-03-27","current":-47.956591,"twenty":-32.06614,"median":-18.561811,"eighty":19.083855,"marketCap":1580265588},{"date":"2026-04-02","current":-41.305964,"twenty":-32.945472,"median":-18.707892,"eighty":19.083855,"marketCap":1723078270},{"date":"2026-04-10","current":-44.675498,"twenty":-33.393759,"median":-19.095844,"eighty":19.083855,"marketCap":1863638401},{"date":"2026-04-17","current":-42.609857,"twenty":-34.004406,"median":-19.561706,"eighty":18.969352,"marketCap":1777470174},{"date":"2026-04-24","current":-43.594639,"twenty":-34.788907,"median":-19.977117,"eighty":18.816681,"marketCap":1818550375},{"date":"2026-05-01","current":-44.030414,"twenty":-35.208457,"median":-20.266831,"eighty":18.756249,"marketCap":1836728722},{"date":"2026-05-08","current":-32.885673,"twenty":-35.663927,"median":-20.816267,"eighty":1.605963,"marketCap":1621165018},{"date":"2026-05-15","current":-34.614036,"twenty":-35.663927,"median":-21.021819,"eighty":-9.854931,"marketCap":1706368150},{"date":"2026-05-22","current":-33.726646,"twenty":-35.536117,"median":-21.24101,"eighty":-10.054175,"marketCap":1662622476},{"date":"2026-05-29","current":-33.709189,"twenty":-35.477208,"median":-21.439742,"eighty":-10.192113,"marketCap":1661761905},{"date":"2026-06-05","current":-33.406604,"twenty":-35.361812,"median":-22.020353,"eighty":-10.267821,"marketCap":1646845348},{"date":"2026-06-12","current":-30.951006,"twenty":-35.258528,"median":-22.098288,"eighty":-10.422477,"marketCap":1525791744},{"date":"2026-06-18","current":-32.769429,"twenty":-35.21133,"median":-22.480166,"eighty":-10.551201,"marketCap":1615434519},{"date":"2026-06-26","current":-39.627064,"twenty":-35.273781,"median":-22.826974,"eighty":-10.561865,"marketCap":1953495352},{"date":"2026-07-02","current":-40.226416,"twenty":-35.557603,"median":-22.973101,"eighty":-10.565696,"marketCap":1983041611},{"date":"2026-07-10","current":-43.944726,"twenty":-36.020976,"median":-23.275097,"eighty":-10.575275,"marketCap":2166343157},{"date":"2026-07-17","current":-42.993327,"twenty":-36.290379,"median":-24.416835,"eighty":-10.577479,"marketCap":2119442057},{"date":"2026-07-24","current":-41.665152,"twenty":-36.922579,"median":-25.632611,"eighty":-10.577479,"marketCap":2053966975},{"date":"2026-07-31","current":-43.697421,"twenty":-37.223591,"median":-27.238059,"eighty":-10.749704,"marketCap":2154151740},{"date":"2026-08-07","current":-36.182159,"twenty":-37.223591,"median":-27.449273,"eighty":-10.795027,"marketCap":2232294496},{"date":"2026-08-14","current":-36.560492,"twenty":-37.14313,"median":-27.55759,"eighty":-10.795594,"marketCap":2255636115},{"date":"2026-08-21","current":-33.297956,"twenty":-36.964247,"median":-27.969419,"eighty":-10.845405,"marketCap":2054350670},{"date":"2026-08-24","current":-33.171845,"twenty":-36.922579,"median":-27.974807,"eighty":-10.857858,"marketCap":2046570130}],"updateTime":1787677275452},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PVLA\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2633141573","title":"Palvella Therapeutics, Inc Q1 EPS USD -1.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2633141573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633141573?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:51","pubTimestamp":1778154691,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nPLX9F2378:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633268149","title":"Earnings Flash (PVLA) Palvella Therapeutics Posts Q1 Net Loss $1.20 a Share, vs. FactSet Est of $0.97 Net Loss a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2633268149","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633268149?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:38","pubTimestamp":1778153886,"startTime":"0","endTime":"0","summary":"Earnings Flash (PVLA) Palvella Therapeutics Posts Q1 Net Loss $1.20 a Share, vs. FactSet Est of $0.97 Net Loss a Share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633499361","title":"Palvella Q1 net loss widens to $15.8 million; R&D expenses rise to $9.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633499361","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633499361?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:34","pubTimestamp":1778153659,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics posted a Q1 net loss of $15.8 million, or $1.20 per share, widening from a $8.2 million loss a year earlier.Research and development expense rose to $9.3 million from $4.1 million, while general and administrative costs climbed to $5.5 million from $3.8 million.Cash, cash equivalents and short-term investments totaled $261.9 million as of March 31, reflecting net proceeds of $215.8 million from a February equity financing.FDA granted a pre-NDA meeting for QTORIN rapamycin in microcystic lymphatic malformations, expected in Q2 2026, with NDA submission still targeted for the second half.Management said it sees potential approval and U.S. commercial launch for QTORIN rapamycin in the first half of 2027 following positive Phase 3 SELVA topline results.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL5MgYS7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","PVLA","LU2210149790.SGD","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633493821","title":"Palvella Therapeutics Q1 EPS $(1.20) Misses $(0.93) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2633493821","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633493821?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153452,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (NASDAQ:PVLA) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(0.93) by 29.03 percent. This is a 62.16 percent decrease over losses of $(0.74) per","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52361425/palvella-therapeutics-q1-eps-1-20-misses-0-93-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149448","title":"Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149448","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633149448?lang=en_us&edition=fundamental","pubTime":"2026-05-07 19:30","pubTimestamp":1778153400,"startTime":"0","endTime":"0","summary":"FDA Pre-New Drug Application (NDA) meeting granted for QTORIN rapamycin for the treatment of microcystic lymphatic malformations, with meeting expected in second quarter of 2026; NDA submission on tra","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/07/3289863/0/en/Palvella-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930284","title":"BRIEF-Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin™ Rapamycin For Clinically Significant Angiokeratomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930284","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930284?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:36","pubTimestamp":1777894586,"startTime":"0","endTime":"0","summary":"BRIEF-Palvella Therapeutics Announces First Patients Dosed In Phase 2 Lotu Trial Of Fast Track-Designated Qtorin Rapamycin For Clinically Significant AngiokeratomasMay 4 (Reuters) - Palvella Therapeut","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUACMSQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632893013","title":"Palvella doses first patients in Phase 2 LOTU trial of QTORIN rapamycin gel","url":"https://stock-news.laohu8.com/highlight/detail?id=2632893013","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632893013?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:31","pubTimestamp":1777894307,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics began dosing first patients in LOTU, a Phase 2 trial testing topical QTORIN rapamycin gel for clinically significant angiokeratomas, a rare condition with no FDA-approved treatments.Study reads out in second half of 2027, with no results reported yet.Trial aims to show safety and clinical improvement versus baseline, targeting symptoms that drive bleeding risk, infection risk, and quality-of-life burden.Program carries FDA Fast Track status, supporting a faster development path if Phase 2 data are positive.Management framed angiokeratomas as a meaningful commercial opportunity, citing more than 50,000 diagnosed patients in US.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL6ncqNz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4112","SG9999014021.USD","SG9999014013.SGD","LU2210149790.SGD","BK4585","BK4139","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632930972","title":"Palvella Therapeutics Inc - Topline Results From Phase 2 Lotu Trial Expected in Second Half of 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2632930972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632930972?lang=en_us&edition=fundamental","pubTime":"2026-05-04 19:30","pubTimestamp":1777894201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nTUACMSQV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631639264","title":"Palvella Therapeutics to host first-quarter financial results conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2631639264","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631639264?lang=en_us&edition=fundamental","pubTime":"2026-04-30 19:34","pubTimestamp":1777548860,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics schedules release of first-quarter 2026 financial results before market open on May 7, 2026.Management to host investor conference call at 8:30 a.m. ET on May 7, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL6SV4nB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BKPKM429.USD","SG9999014021.USD","IE00BGHQF748.EUR","LU2095319765.USD","BK4585","NDAQ","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","PVLA","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","BK4588","LU2210150020.SGD","BK4139","LU0314104364.USD","SG9999014039.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630538870","title":"Is It Too Late To Consider Palvella Therapeutics (PVLA) After Its 386.8% One Year Surge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2630538870","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630538870?lang=en_us&edition=fundamental","pubTime":"2026-04-26 09:15","pubTimestamp":1777166128,"startTime":"0","endTime":"0","summary":"Wondering whether Palvella Therapeutics at around US$123.59 still offers value, or if most of the easy gains are already behind it? This article walks through what the current price could mean for you.\nThe stock has seen a 23.2% return year to date and a 386.8% return over the last year, alongside shorter term moves of a 2.7% return over 30 days and a 4.9% decline over the past week.\nRecent attention on Palvella Therapeutics has centered on how the market is reassessing smaller biotech names...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pvla/palvella-therapeutics/news/is-it-too-late-to-consider-palvella-therapeutics-pvla-after","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pvla/palvella-therapeutics/news/is-it-too-late-to-consider-palvella-therapeutics-pvla-after","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FCF","BK4211","DCF","BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629412036","title":"Analysts Offer Insights on Healthcare Companies: Agios Pharma (AGIO) and Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629412036","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629412036?lang=en_us&edition=fundamental","pubTime":"2026-04-21 20:00","pubTimestamp":1776772832,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agios Pharma (AGIO) and Palvella Therapeutics (PVLA)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-agios-pharma-agio-and-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-agios-pharma-agio-and-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","LABU","LU0029874061.USD","LU0128526141.USD","XLV","BK4585","AGIO","BK4139","XBI","BK4581","BK4588","PVLA","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628174750","title":"Palvella reports Phase 3 SELVA, Phase 2 TOIVA QTORIN rapamycin results slated for ISSVA 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2628174750","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628174750?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:30","pubTimestamp":1776684648,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics flagged late-breaking clinical results for QTORIN rapamycin gel from Phase 3 SELVA and Phase 2 TOIVA studies for presentation at ISSVA World Congress 2026.Data will be presented May 20, 2026 at 4:30 p.m. ET in Philadelphia.Studies showed statistically significant, clinically meaningful improvement in microcystic lymphatic malformations.Results also indicated clinically meaningful improvement in cutaneous venous malformations.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260420:nNDL7c5Zx0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","IE00BN0W2T93.GBP","LU0314104364.USD","SG9999014005.SGD","LU2210149790.SGD","NDAQ","BK4588","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","BK4585","BK4112","IE00BKPKM429.USD","SG9999014021.USD","IE00BN0W2V16.EUR","PVLA","BK4139","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628406781","title":"Palvella COO Kathleen Goin disposes of 4,302 shares worth $549,900","url":"https://stock-news.laohu8.com/highlight/detail?id=2628406781","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628406781?lang=en_us&edition=fundamental","pubTime":"2026-04-18 04:06","pubTimestamp":1776456361,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics COO Kathleen Goin reported exercising stock options to acquire 4,302 common shares on April 15, 2026 at USD 7.14 to USD 9.08 per share.She reported selling 4,302 common shares on April 15, 2026 at weighted average prices ranging from about USD 125.96 to USD 130.33.Goin reported ending April 15, 2026 with 0 common shares beneficially owned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260417:nNDL13Qqf0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Palvella COO Kathleen Goin disposes of 4,302 shares worth $549,900","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627237413","title":"Palvella Therapeutics director John Doux files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2627237413","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627237413?lang=en_us&edition=fundamental","pubTime":"2026-04-16 04:06","pubTimestamp":1776283564,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics director John Doux reported a fully vested stock option for 10,364 common shares at USD 7.14, expiring Feb. 4, 2030.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 15, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260415:nNDL32FZQW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627948437","title":"Press Release: Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2627948437","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627948437?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:30","pubTimestamp":1776079800,"startTime":"0","endTime":"0","summary":"Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership. \"We are honored to welcome John to our Board as we build Palvella toward our vision of becoming the leading rare disease biopharmaceutical company focused on serious skin diseases and vascular malformations with no FDA-approved therapies,\" said Wes Kaupinen, Founder and Chief Executive Officer of Palvella Therapeutics. \"John is a highly respected dermatologist and investor who has long been a leading, vocal advocate for the development of novel therapies for rare skin diseases. He brings deep compassion and care from years of treating patients with rare diseases, along with a clear understanding of the profound unmet need across these conditions. His perspective will be especially valuable as we continue to expand our pipeline and the QTORIN platform.\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4555","TM","BK4099","BK4022","BK4604","BK4588","BK4232","03160","BK4585","BK4139","PVLA","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937572","title":"Press Release: Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937572","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937572?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:30","pubTimestamp":1775561400,"startTime":"0","endTime":"0","summary":"Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics , where he led U.S. sales efforts for ZORYVE, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte  supporting the launch of OPZELURA. Mr. Taylor to lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN rapamycin for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S.\"Kent's leadership and performance helped shape two of the most successful dermatology launches in recent years, ZORYVE and OPZELURA, and he brings deep experience partnering with dermatologists, including pediatric dermatologists, who often diagnose and treat patients with microcystic lymphatic malformations,\" said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. \"We are thri","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624919549","title":"Palvella director George M. Jenkins acquires PVLA shares worth 0.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624919549","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624919549?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:06","pubTimestamp":1775074010,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics director George M. Jenkins reported an open-market purchase of 445 common shares at USD 112.3 per share.Directly held stake rose to 187,616 common shares following transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL8RZCMS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Palvella director George M. Jenkins acquires PVLA shares worth 0.1 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PVLA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187347316","title":"Stock Track | Palvella Therapeutics Soars 5.58% Intraday on Analyst Price Target Hikes","url":"https://stock-news.laohu8.com/highlight/detail?id=1187347316","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187347316?lang=en_us&edition=fundamental","pubTime":"2026-04-01 21:35","pubTimestamp":1775050548,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) saw its stock price soar 5.58% during intraday trading on Wednesday, driven by positive analyst sentiment.The surge follows pre-market announcements from two research...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590664","title":"Palvella Therapeutics Inc : Raymond James Raises Target Price to $225 From $193","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590664","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590664?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:19","pubTimestamp":1775042380,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nFWN40K0QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PVLA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590589","title":"Chardan Raises Price Target on Palvella Therapeutics to $240 From $210, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590589","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590589?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:15","pubTimestamp":1775042122,"startTime":"0","endTime":"0","summary":"Palvella Therapeutics (PVLA) has an average rating of buy and mean price target of $229.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PVLA"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":9,"pageCount":5,"totalSize":164,"code":"91000000","status":"200"}]}}